tirzepatide and methotrexate Results of the phase 3b TOGETHER-PsA trial showed ixekizumab administered together with in comorbid overweight or obese adults with psoriatic arthritis showed clinically meaningful improvement of psoriatic disease, physical function, weight Tirzepatide Injections for Medical Weight

Modified-release formulations are available and may be better tolerated by some patients

10.1002/ana.410440716 17 BerryC.La VecchiaC.NicoteraP

Athletic testing will

3.4 Research Applications TB-500 has been investigated in a wide range of laboratory models: 4

### How Each Drug Performs at Key Milestones | Milestone | Orforglipron (36 mg) | Oral Semaglutide (50 mg) | Tirzepatide (15 mg) | |-----------|---------------------|-------------------------|---------------------| | **4 weeks** | ~2-3% | ~2-3% | ~3-4% | | **12 weeks** | ~6-8% | ~6-7% | ~8-10% | | **24 weeks** | ~10-12% | ~10-11% | ~14-16% | | **36 weeks** | ~14-15% | ~12-13% | ~17-19% | | **68-72 weeks** | ~15%+ (projected) | ~15.1% | ~20-22.5% | For detailed semaglutide weight loss trajectories, see our [semaglutide weight loss results timeline](/guides/semaglutide-weight-loss-results-timeline-what-to-expect)

[112] Jarrard D, Filon M, Huang W, et al